Momelotinib

OJJAARA is indicated for the treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF or secondary MF [post‑polycythemia vera (PV) and post‑essential thrombocythemia (ET)], in adults with anemia.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: OJJAARA is indicated for the treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF or secondary MF [post‑polycythemia vera (PV) and post‑essential thrombocythemia (ET)], in adults with anemia.

Side effects, and when to stop

The following clinically significant adverse reactions are described elsewhere in the labeling:

Risk of Infections and Hepatitis B Reactivation
Thrombocytopenia and Neutropenia
Hepatotoxicity
Severe Cutaneous Adverse Reactions
Major Adverse Cardiovascular Events
Thrombosis
Malignancies
Symptom Exacerbation Following Interruption or Discontinuation of Treatment

Who should not take it

None.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Momelotinib; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/momelotinib
APA 7th: sofidex. (2026, August 3). Momelotinib. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/momelotinib
AMA 11th: Momelotinib. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/momelotinib

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.